Introduction
Tumor necrosis factor (TNF)-a, CD95L (FasL/Apo-1L) and Apo2 ligand/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) are members of a growing family of cytokines that are cytotoxic to certain cancer cells (Ashkenazi and Dixit, 1998) . These cytokines interact with one or several cell surface receptors to trigger a killing cascade that depends critically on the activation of caspases and probably involves the mitochondrial release of cytochrome c in most cell lines. During CD95L-induced apoptosis, CD95L interacts with and induces trimerization of the receptor CD95. Oligomerized CD95 binds the adapter protein, Fas-associating protein with death domain (FADD) , that recruits caspase 8, triggering a cascade of caspase activation that ®nally leads to cell death. Only some cells respond to CD95 triggering with an activation of caspase 8 that is sucient to directly induce cell death (type I cells) (Scadi et al., 1998) . Most cells appear to require a mitochondrial ampli®cation step for the execution of apoptosis (type II cells). According to this concept, type II cells are protected from CD95-mediated apoptosis by BCL-2 or BCL-X L whereas type I cells are not. Consequently, malignant glioma cell lines can be classi®ed as type II cells (Weller et al., 1995a) . In type II cells, a moderate activation of caspase 8 leads to the release of cytochrome c from mitochondria (Kuwana et al., 1998) which in complex with apoptosis-activating factor (APAF)-1 activates the initiator caspase 9 and enhances the activation of the caspase cascade (Li et al., 1997; Saleh et al., 1999) .
The sensitivity of cancer cells to cytotoxic cytokineinduced apoptosis is subject to complex regulatory processes. First, the absence or presence of cell surface receptors for these cytokines determines whether cancer cells will respond to the cytokines or not. Second, a growing number of antiapoptotic proteins which can interfere with cytokine-mediated killing pathways have been identi®ed, e.g., BCL-2 family proteins, viral caspase inhibitors such as crm-A, IAP proteins or FLIP. The antiapoptotic function of such proteins has mostly been characterized by gene transfer studies where these proteins were expressed at high levels. Using this approach, BCL-2, crm-A and XIAP were shown to inhibit TNF-a-, CD95L-and Apo2L/ TRAIL-mediated apoptosis in human glioma cells (Weller et al., 1995a; Rieger et al., 1998; Wagenknecht et al., 1999 ). An important role for endogenous cellular proteins in inhibiting cytotoxic cytokineinduced apoptosis is suggested by the observation that inhibition of mRNA or protein synthesis greatly enhances sensitivity to TNF-a, CD95L or Apo2L/ TRAIL in glioma cells (Weller et al., 1994; . Interestingly, BCL-2 and XIAP levels are not signi®cantly lowered by exposure to CHX alone under experimental conditions where CHX sensitizes glioma cells to cytotoxic cytokine-induced apoptosis. Thus, it has remained unclear which short-lived proteins mediate protection from death receptormediated apoptosis and at which level these proteins interact with the death receptor-dependent killing cascade.
In the present study, we analysed the CD95-mediated signaling cascade in two human malignant glioma cell lines, LN-18 and LN-229, which dier dramatically in their requirement for inhibition of protein synthesis to respond to exogenous CD95L with cell death. While LN-18 cells are highly sensitive to CD95L, LN-229 cells are rather resistant to CD95-mediated apoptosis unless coexposed to CD95L and CHX. We characterize at least two targets of CHX, (i) potentiation of caspase 8 activation at the receptor in LN-229 cells and (ii) a down-stream target at least in LN-18 cells, but probably in both cell lines, that may be identical with the CDK inhibitor, p21 Waf/Cip1 .
Results

Inhibition of protein synthesis facilitates CD95-mediated apoptosis of human malignant glioma cells upstream of mitochondrial cytochrome c release
We have previously characterized a panel of human malignant glioma cell lines for their susceptibility to CD95-mediated apoptosis (Weller et al., 1994; Rieger et al., 1998) . LN-18 cells are very sensitive to induction of apoptosis whereas LN-229 cells are rather resistant to CD95-mediated apoptosis, unless coexposed to inhibitors of RNA and protein synthesis ( Figure 1 ). All glioma cell lines, which express CD95, show enhanced apoptosis when RNA and protein synthesis are inhibited, suggesting the presence of short-lived cytoprotective proteins which interfere with the CD95-evoked killing cascade . To identify the sites where these putative proteins act, we compared the biochemical steps evoked by CD95L in LN-18 and LN-229 cells which are paradigmatic for dierential requirement for inhibition of protein synthesis for apoptosis to evolve. In LN-18 cells cultured in the absence of CHX, CD95L induced the release of cytochrome c from mitochondria and the processing of caspases 3, 7, 8 and 9, as well as of the caspase 3 substrate, poly-ADP-ribose polymerase (PARP), and the caspase 1/8 substrate, Bap31, with a similar time course (Figure 2 , left panels). These events were enhanced in the presence of CHX. None of these changes were observed in CD95L-treated LN-229 cells in the absence of CHX, except for mild partial processing of caspase 8 to p43/caspase 8 and of caspase 3 to p24/caspase 3 (Figure 2 , right panels). However, coexposure to CD95L and CHX induced the same biochemical changes in LN-229 cells that were observed in LN-18 cells exposed to CD95L alone.
Delayed BID cleavage during CD95-mediated apoptosis in glioma cells
Recent studies have implicated BID as a cytoplasmic mediator of mitochondrial cytochrome c release during Note that CHX alone is devoid of toxicity under these conditions CD95-mediated apoptosis, e.g., of Jurkat T cells and HeLa cells Li et al., 1998; Luo et al., 1998; Gross et al., 1999) . We ®nd that BID is cleaved in LN-18, but not in LN-229 cells, in the absence of CHX, but in both cell lines in the presence of CHX (Figure 3a) . In LN-18 cells, the 22 kDa fulllength BID protein was cleaved into the proapoptotic 15 kDa fragment at 4 h after treatment with CD95L in the absence or presence of CHX. In contrast, BID cleavage in LN-229 became only apparent by a slight decrease of the full-length BID protein starting at 4 h after treatment with CD95L in the presence of CHX. As a control, the cleavage of BID during CD95L-induced apoptosis was monitored in Jurkat cells Luo et al., 1998) . At 1 h after treatment with CD95L, the proapoptotic 15 kDa truncated form of BID (tBID) was detected which was further cleaved into a smaller fragment (p13). In parallel, the levels of the full-length BID protein decreased in a timedependent manner (Figure 3b ). Coexposure to z-VAD-fmk prevented BID processing and maintained the levels of full-length BID in Jurkat cells. Of note, Figure 2 Requirement for inhibition of protein synthesis for CD95L-mediated caspase activation and cytochrome c release in LN-229, but not LN-18, cells. LN-18 (left) or LN-229 (right) cells were exposed to CD95L (10 U/ml for LN-18, 100 U/ml for LN-229) in the absence or presence of CHX (10 mg/ml). Immunoblot analyses were performed for caspase 8, caspase 3, PARP, Bap31, caspase 9, caspase 7 and cytosolic cytochrome c as described in Materials and methods. Processing of caspases and substrates is re¯ected by the detection of p18/caspase 8, p17/caspase 3, p85/PARP, p20/Bap31, p37/p35/caspase 9 and p20/caspase 7. Note that LN-229 cells showed a smaller unspeci®c band migrating at 35 kDa in most experiments examining caspase 9 BID cleavage represented a late event during CD95-mediated apoptosis in glioma cells compared with Jurkat T cells. Further, BID seemed not be cleaved in a quantitative manner in glioma cells, but only to a minor extent.
Cleavage of antiapoptotic proteins during CD95-mediated apoptosis
Cleavage of antiapoptotic proteins such as BCL-2 (Kirsch et al., 1999) , BCL-X L (Clem et al., 1998; Fujita et al., 1998) , XIAP (Deveraux et al., 1999) or FLIP (Irmler et al., 1997; Srinivasula et al., 1997) may play a central role in the apoptotic process in mammalian cells. These candidate substrates for activated caspases were also examined here. LN-18 and LN-229 cells were treated with CD95L in the absence or presence of CHX, and alterations of the levels of the respective proteins were examined by immunoblot analysis (Figure 3c ). The levels of BCL-2 and FLIP were virtually unchanged in response to CD95L in both cell lines, either in the absence or presence of CHX. Notably the levels of FLIP have been suggested to rapidly decrease in response to CHX, thus allowing death receptor-mediated cell death to proceed (Fulda et al., 2000; Grith et al., 1998; Leverkus et al., 2000; Wajant et al., 2000) . Therefore, we examined a possible change of FLIP levels in response to CHX at increasing concentrations or at dierent lengths of exposure but we con®rmed the absence of changes in FLIP levels within the time frame of our experiments ( Figure 3d ). In contrast, the level of BCL-X L decreased, and XIAP was cleaved, in response to CD95L under conditions that induced cell death, that is, in LN-18 cells exposed to CD95L in the absence or presence of CHX, and in LN-229 only after coexposure to CD95L and CHX ( Figure 3c ). The BCL-X L protein was detected as a doublet band with a molecular weight ranging from 29 ± 31 kDa, consistent with previous reports (Krajewski et al., 1994; Kondo et al., 1998) . A stable cleavage product of BCL-X L was not detected with two dierent antibodies tested, recognizing either the NH 2 -terminal or the COOHterminal region of BCL-X L . The decrease of BCL-X L protein was inhibited by the caspase inhibitor z-VADfmk (Figure 3e ), indicating that BCL-X L protein is cleaved by caspases. The 53 kDa XIAP protein was cleaved to generate a 30 kDa product as previously observed in Jurkat T cells (Deveraux et al., 1999) . were exposed to CD95L (10 U/ml for LN-18, 100 U/ml for LN-229) in the absence or presence of CHX (10 mg/ml) for 6 h. Immunoblot analysis for BCL-2, BCL-X L , FLIP or XIAP was performed as described in Materials and methods. Actin was used as a protein loading control, *indicates a positive control for the cleavage of XIAP, this is, Jurkat T cells treated with CD95L. (d) The cells were treated with CHX at increasing concentrations for 16 h (left), or at 10 mg/ml for 0 ± 16 h, and assessed for FLIP levels as in a. (e) LN-18 or LN-229 cells treated as in a, but with or without z-VAD-fmk (50 mM), were analysed for the level of BCL-X L protein Inhibition of CD95-mediated apoptosis by BCL-X L and crm-A: effects on caspase activation and cytochrome c release To further dissect the CD95-dependent killing pathway in glioma cells, we generated transfected sublines engineered to express a human BCL-X L transgene or the viral caspase 8-selective caspase inhibitor, crm-A (Figure 4a ). These cell lines were protected from CD95-mediated cell death both in the absence or presence of CHX (Figure 4b ,c). Both crm-A and BCL-X L inhibited the release of cytochrome c in response to CD95L in either cell line (Figure 5a ). Figure 5b shows the eects of ectopic crm-A and BCL-X L expression on caspase 3, 8 and 9 activation. Crm-A prevented the processing of caspases 3, 8 and 9 in both cells lines. In contrast, BCL-X L strongly reduced the processing of caspase 8 in LN-18 cells, both in the absence and presence of CHX, but had no eect on caspase 8 cleavage in the presence of CHX in LN-229 cells. Further, the processing of caspase 3 was not fully abrogated but blocked by BCL-X L in both cell lines at an intermediate step, resulting in the formation of a *24 kDa caspase 3 fragment. The processing of caspase 9 was completely blocked by BCL-X L in both cell lines.
Involvement of p21 in CD95L-mediated apoptosis
Previous work from our laboratory suggested a role for the CDK inhibitor, p21, in mediating resistance to chemotherapy in glioma cells . Here, we observed that exposure to CHX alone decreased p21 levels within 30 min of exposure in both cell lines (Figure 6a ). Further, coexposure to CHX and CD95L resulted almost in a complete loss of p21, suggesting that p21 is also a target for caspasemediated degradation (Figure 6b ). To examine a biological role of endogenous p21 in the modulation of CD95-mediated apoptosis, we made use of p21 antisense oligonucleotides encoding a previously published sequence complementary to the p21 mRNA (Poluha et al., 1996) . As shown in Figure 6c , LN-18 and LN-229 cells treated with p21 antisense oligonucleotides showed a strong decrease of p21 protein levels compared with the control sense oligonucleotides or with untransfected cells. Transfection of LN-18 and LN-229 cells with p21 antisense oligonucleotides increased their sensitivity to CD95L dramatically, to an extent comparable to the eect of CHX (Figure 6d , for comparison, see Figure 1c ,d). To extend these data and con®rm their speci®city, we veri®ed that CD95-mediated apoptosis was also potentiated by p21 6e). Immunoblot analysis revealed that the treatment with p21 antisense oligonculeotides facilitated the activation of caspases 8, 3, 9 and 7, as well as mitochondrial cytochrome c release (Figure 6f) , in a manner similar to CHX (Figure 2) . Further, similar to CHX (Figure 3a) , p21 antisense oligonculeotides induced a delayed loss of BID protein in DC95L-treated LN-229 cells. Eventually, the activation of caspases in response to p21 antisense oligonculeotide treatment was con®rmed at the level of caspase activity measured in a DEVD-amc cleavage assay (Figure 6g ).
Discussion
Cellular sensitivity to apoptosis-inducing cytokines such as TNF-a, CD95L or Apo2L/TRAIL is determined by the expression of speci®c cytokine receptors and the levels of as yet unidenti®ed short-lived cellular proteins which interfere with the death receptordependent killing pathway. The latter assumption is based on the observation that inhibition of RNA or protein synthesis greatly enhances death receptormediated apoptosis in many cell lines. Thus, when new protein synthesis is inhibited, expression of CD95 at the cell surface is a fairly good predictor of glioma cell sensitivity to CD95L-induced apoptosis (Weller et al., 1995b) .
The interaction of CD95L with CD95 results in autoprocessing and activation of caspase 8 (Ashkenazi and . Active caspase 8 may directly engage the caspase cascade by activating caspase 3. Alternatively, caspase 8 can also activate other caspases indirectly, e.g., by inducing cytochrome c release from mitochondria (Scadi et al., 1998) . Cytochrome c released into the cytoplasm binds and activates APAF-1 and caspase 9, resulting in the activation of caspase 9 and the consecutive activation of a branched caspase cascade involving caspase 3 (Li et al., 1997; Slee et al., 1999) .
In the present study, two glioma cell lines with a dierential requirement for inhibition of protein synthesis for cell death were employed to identify how inhibition of protein synthesis facilitates CD95-mediated apoptosis. LN-18 cells die readily in response to CD95L whereas LN-299 cells are fairly resistant to CD95L unless coexposed to CHX (Figure 1) . Time kinetic studies revealed that CD95L induced mitochondrial cytochrome c release, processing of caspases 3, 7, 8 and 9, and cleavage of the caspase 3 substrate, PARP, and the caspase 1/8 substrate, Bap31, concurrently in LN-18 cells in the absence or presence of CHX. In contrast, none of these events was observed to a comparable degree in LN-229 cells in the absence of CHX (Figure 2 ). These data indicate that the time course of cytochrome c release, processing of activator caspases such as caspases 8 or 9, and processing of executor caspases such as caspases 3 or 7 cannot be dissected during CD95-mediated apoptosis of glioma cells. Further, these data place the inhibition of protein synthesis as a facilitating factor upstream of all these events. BID is a cytosolic protein that may induce cytochrome c release when cleaved to the proapoptotic truncated p15 form (tBID) by caspase 8 in Jurkat T cells Luo et al., 1998) . CD95L-induced cytochrome c release in glioma cells was eectively prevented by the caspase 8-speci®c inhibitor, crm-A (Figure 5a ) and by the broad-spectrum peptide caspase inhibitor, z-VAD-fmk (data not shown), suggesting that caspase 8 or other caspases initiate cytochrome c release in this system. Caspase 8-induced BID cleavage is unlikely to be the mediator of cytochrome c release during CD95-mediated apoptosis in glioma cells since the time-dependent pro®le of BID cleavage (Figure 3a ) did not correlate with the activation of caspase 8 (Figure 2 ) and since BID cleavage occurred later than the release of cytochrome c (Figure 2 ). Although we cannot exclude that minor levels of BID cleavage, that escaped the sensitivity of our analysis, triggered cytochrome c release in glioma cells, our data are in agreement with recent reports which describe BID cleavage after cytochrome c release (Granville et al., 1999) and cytochrome c release triggered by caspases and mediated by cytosolic substrates presumably dierent from BID (Bossy-Wetzel and Green, 1999).
Neither BCL-2, BCL-X L , XIAP nor FLIP levels were decreased by CHX treatment alone within the time frame of the experiments (Figure 3c ), suggesting that these proteins are not the short-lived proteins which are the target of CHX-mediated potentiation of CD95-mediated apoptosis. Notably the absence of changes in FLIP levels (Figure 3d ) in response to CHX contrasts with previous studies in nonglial cells (Fulda et al., 2000; Grith et al., 1998; Leverkus et al., 2000; Wajant et al., 2000) .
Interestingly, while the levels of the BCL-2 and FLIP proteins were unaltered during apoptosis, the BCL-X L protein level decreased, and XIAP was cleaved, in response to CD95L strictly under conditions associated with cell death, that is, in LN-18 cells exposed to CD95L either in the absence or presence of CHX, but in LN-229 cells only in the presence of CHX. The loss of BCL-X L was prevented by caspase inhibition (Figure 3e ), indicating that caspases are critically involved in this modulation of BCL-X L expression. These data support the notion that the antiapoptotic BCL-X L protein is a substrate for caspases, e.g., caspase 3, in cells undergoing apoptosis. The cleavage product of BCL-X L has been proposed to exert a death-promoting function which accelerated the apoptotic process (Clem et al., 1998; Fujita et al., 1998) . XIAP was processed to a 30 kDa fragment. Caspasemediated XIAP cleavage during CD95-mediated apoptosis in Jurkat T cells may generate two products which comprise the baculoviral inhibitory repeat (BIR)-1 and -2 domains (BIR-1/2) and the BIR-3 and RING (BIR-3-RING) domains. The BIR-1/2 fragment has a reduced capability to inhibit caspase activation compared with full-length XIAP and has therefore a diminished ability to suppress apoptosis (Deveraux et al., 1999) .
Ectopic crm-A expression inhibited mitochondrial cytochrome c release and almost completely abrogated the processing of caspases 3, 8 and 9 in both cell lines (Figure 5 ), con®rming that caspase 8, or a related crm-A-sensitive caspase, represents the initiator caspase during CD95-mediated apoptosis in glioma cells. BCL-X L inhibited cytochrome c release and processing of caspase 9 in both cell lines but did neither prevent the partial processing of caspase 3 to a 24 kDa fragment in either cell line nor the processing of caspase 8 in LN-229 cells coexposed to CD95L and CHX. The concurrent inhibition of mitochondrial cytochrome c release and caspase 9 processing by BCL-X L is consistent with the notion that cytochrome c cooperates with APAF-1 to mediate caspase 9 activation (Li et al., 1997; Saleh et al., 1999; Zou et al., 1999) and that this sequence of events is blocked by the BCL-X Ldependent prevention of mitochondrial cytochrome c release (Kluck et al., 1997; Yang et al., 1997) . Caspase 3 processing evolves in two steps, involving an initial cleavage by caspase 8 or caspase 9, that generates the partially processed p24 large subunit and the p12 small subunit. p24/caspase 3 is further processed by autocatalytic removal of the pro-domain to generate the active p17 form (Martin et al., 1996; Deveraux et al., 1997; Slee et al., 1999) . Ectopic expression of BCL-X L strongly attenuated caspase 8 activation in LN-18 cells but had no eect on caspase 8 activation in LN-229 cells (Figure 5b ). Yet, BCL-X L blocked processing of caspase 3 to the active p17 fragment in both cell lines. This indicates that caspase 3 may not be processed to the active p17 by caspase 8 but requires the release of mitochondrial cytochrome c and subsequent activation by caspase 9 for full processing. It is also conceivable that forced expression of BCL-X L inhibits caspase 3 autoproteolytic activation to the active p17 fragment through a direct interaction with the partially processed p24/caspase 3. Since BCL-X L is cleaved by caspases during cell death induced by CD95L in glioma cells, con®rming physical interaction between these proteins (Figure 3e ), the direct interaction of BCL-X L with caspases may be an important mechanism of inhibiting cell death and the ratio of full-length to cleaved BCL-X L may determine susceptibility to cell death.
LN-18 cells activated caspase 8 to a lower extent when the mitochondrial pathway was blocked by ectopic BCL-X L expression even in the presence of CHX, suggesting that the activation of caspase 8 is ampli®ed through the mitochondria-dependent activation of caspase 3 and that CHX acts downstream of the activation of caspase 8 in this cell line. Conversely, CHX enhanced the processing of caspase 8 independently of the BCL-X L -sensitive mitochondrial pathway in LN-229 cells, and the inhibition of caspase 3 processing by BCL-X L was not accompanied by changes in caspase 8 processing. Thus, caspase 8 is chie¯y activated upstream of mitochondria in LN-229 cells, and CHX appears to act at the level of caspase 8 activation. It is conceivable that the target of CHX is a caspase 8-or FADD-inhibitory protein which is not (Irmler et al., 1997; Scadi et al., 1999) . However, FLIP was not cleaved in response to CD95L, and the FLIP protein level was not in¯uenced by CHX (Figure 3c,d) , excluding FLIP as a target of CHX which when reduced in protein level allows for caspase 8 activation during CD95L-mediated apoptosis in human glioma cells. Recently, a new protein, FLICEassociated huge protein (FLASH), was identi®ed that is capable of binding caspase 8 at the death-inducing signaling complex and that is required for the activation of caspase 8 during CD95-mediated apoptosis (Imai et al., 1999) . The modulation of FLASH activity by a CHX-sensitive protein could possibly mediate caspase 8 activity in CD95L-treated LN-229 cells. Thus, the present study places inhibition of protein synthesis as a facilitating factor for CD95-mediated apoptosis upstream of mitochondrial cytochrome c release and at the level of caspase 8 activation in LN-229 cells, but suggests a second BCL-X L -sensitive mode of potentiation of apoptosis by CHX which operates in LN-18 cells.
Several recent studies have delineated an antiapoptotic activity of the CDK inhibitor, p21 (Waf/Cip1), in various paradigms of apoptosis (Gorospe et al., 1996; Naumann et al., 1998; Ruan et al., 1998; Asada et al., 1999; Wang et al., 1999; Zhang et al., 1999a) . The mechanism of p21-mediated inhibition of CD95-mediated apoptosis has remained controversial but may involve complex formation with caspase 3 (Suzuki et al., 1998 (Suzuki et al., , 1999a (Suzuki et al., ,b, 2000a . Conversely, cleavage and inactivation of p21 by caspase 3 has been suggested to accelerate apoptosis (Gervais et al., 1998; Levkau et al., 1998; Park et al., 1998; Zhang et al., 199b) . Here, we show that CHX induces a rapid loss of p21 in both glioma cell lines (Figure 6a ) and that transfection with antisense oligonucleotides directed against the p21 sense transcript results in prominent sensitization to CD95-mediated apoptosis (Figure 6d ). In fact, the eects of p21 antisense oligonucleotides are as strong as those of CHX (Figure 1 ), raising the possibility that p21 is the principle mediator of CHX-dependent potentiation of CD95-mediated apoptosis in glioma cells. Similar results to those obtained with LN-18 and LN-229 cells were obtained with CD95-expressing T98G glioma cells, but not with LN-308 cells, which express almost no CD95 at the cell surface (Weller et al., 1995b) (Figure 6e ), demonstrating the speci®c sensitization to CD95L-induced apoptosis by p21 antisense oligonucleotides.
Interestingly, although p21 is a potent cell cycle regulatory protein, we have previously observed that CD95-mediated apoptosis of glioma cells is cell cycleindependent (Hueber et al., 1998 ). Yet, the role of p21 for the cell cycle regulation in glioma cell lines is debatable since p21 feeds into the retinoblastoma (RB) cell cycle checkpoint which is disrupted in almost all glioma cell lines. For instance, LN-18 and LN-229 cells have a deletion of the p16 genes, and LN-229 cells show enhanced expression of CDK-4 . Therefore, the targets for p21-mediated growth inhibition in G0/1 are deregulated in glioma cells.
Taken together, the dierential sensitivity of CD95L-sensitive LN-18 cells and CD95L-resistent LN-229 cells may result from a dierent extent of caspase 8 activation at the receptor level. The failure to eciently activate caspase 8 can be overcome by CHX-mediated inhibition of protein synthesis. At least one presumptive target of CHX, a short-lived protein that prevents caspase 8 activation in LN-229 cells, may not be active or at least less active in LN-18 cells which activate caspase 8 even in the absence of CHX. Further, CHXinduced potentiation of CD95-induced apoptosis can also be mediated by an eect of CHX downstream of caspase 8 activation, at least in LN-18 cells, that is most likely the rapid loss of p21 levels in the presence of CHX which in turn greatly facilitates caspase activation.
Materials and methods
Chemicals and cell lines
CHX was obtained from Sigma (St. Louis, MO, USA). The broad spectrum caspase inhibitor benzyloxycarbonyl-val-alaasp(OMe)-¯uoromethylketone (z-VAD-fmk), and the caspase 3 substrate, acetyl-asp-glu-val-asp-chloromethylcoumarin (ac-DEVD-amc), were from Bachem (Heidelberg, Germany). CD95L was obtained from murine CD95L-transfected murine N2A neuroblastoma cells. The activity of this supernatant may depend on the presence of aggregates of membrane type, not processed soluble CD95L (Schneider et al., 1998) . The human malignant glioma cell lines LN-18, LN-229, LN-308 and T98G were kindly provided by Dr N de Tribolet (Lausanne, Switzerland). The cells were maintained in DMEM containing 10% FCS and penicillin (100 IU/ml)/ streptomycin (100 mg/ml) (Weller et al., 1994; Glaser et al., 1999) . The generation of glioma cell sublines expressing crm-A has been described (Wagenknecht et al., 1998) . Glioma cell sublines engineered to express human BCL-X L were obtained by electroporation (Biorad Gene Pulser, 250 V, 950 mF) using the pSFFV-BCL-X L plasmid, kindly provided by CB Thompson (Chicago, IL, USA) or the empty neo plasmid as a control. Transgene expression was assessed by immunoblot analysis.
analyses were performed for processing of caspases 8, 3, 9 or 7, for cytosolic cytochrome c, or for BID levels. Control refers to cells treated with sense or antisense oligonucleotides only for 8 h. 
Viability assays
The cells were seeded at 10 4 cells per well in 96 well plates, adhered for 24 h and exposed to CD95L in the absence or presence of CHX (10 mg/ml). Survival was assessed by crystal violet staining. Brie¯y, the supernatant was removed, and the cells were incubated for 10 min in crystal violet solution (2%) in 20% methanol. The plates were washed in running tap water and air-dried for 24 h. After addition of 0.1 M sodium citrate buer, OD values were read at 550 nm on a Dynatech plate photometer.
DEVD-amc cleavage assay
The cells were seeded at 10 4 cells per well in 96 well plates, adhered for 24 h and were then transfected with p21 sense or antisense oligonucleotides (0.3 mM, 16 h). Then the medium was removed, and the cells were treated with CD95L. After the indicated time points the cells were incubated in lysis buer (25 mM Tris/HCL, pH 8.0, 60 mM NaC1, 2.5 mM EDTA, 0.25% NP40) for 10 min. The¯uorogenic caspase 3 substrate, ac-DEVD-amc (12.5 mM), was added, and thē uorescence was determined in 15 min intervals using 360 nm excitation and 480 nm emission wavelengths in a CytoFluor 2300 (Millipore, Eschborn, Germany).
Immunoblot analysis
Immunoblot studies were performed according to standard procedures (Weller et al., 1994) . The following antibodies were used at the indicated concentrations: mouse monoclonal anti-human caspase 3 (1 : 1000; Transduction Laboratories, Lexington, KY, USA), mouse monoclonal anti-human caspase 8 (C15; 1 : 5; kindly provided by PH Krammer, Heidelberg, Germany), mouse monoclonal anti-human caspase 7 and 9 antibodies (1 : 1000; Cold Spring Harbor, NY, USA) (Fearnhead et al., 1998) , rabbit polyclonal anti-BID antibody (1 : 2000; Howard Hughes Medical Institute and Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, TX, USA) (Luo et al., 1998) , rabbit polyclonal anti-human XIAP (1 : 2000; kindly provided by P Liston, Ottawa, Ontario, Canada) , rabbit polyclonal anti-human Bap31 (1 : 500; kindly provided by GC Shore, Montreal, Canada) (Ng et al., 1997) , goat polyclonal anti-human actin (2.0 mg/ ml; Santacruz, San Diego, CA, USA), mouse monoclonal anti-bovine cytochrome c oxidase subunit IV (1 mg/ml; Molecular Probes, Eugene, OR, USA), rabbit polyclonal anti-human FLIP, mouse monoclonal anti-human BCL-2, crm-A, PARP and cytochrome c (2 mg/ml; PharMingen, San Diego, CA, USA). We used two mouse monoclonal antihuman BCL-X L antibodies recognizing either the NH 2 -terminal region (2 mg/ml; PharMingen) or the COOHterminal region of BC1-X L (1 : 500; Transduction Laboratories, Lexington, KY, USA). Experiments using these dierent antibodies yielded identical results. Protein A and anti-mouse IgG were purchased from Amersham (Braunschweig, Germany), anti-goat IgG was from Santacruz. Enhanced chemiluminescence (ECL) reagents (Amersham) were used for detection.
Measurement of cytochrome c release
The cells were treated as indicated, washed with PBS and lysed for 5 min at 48C in 210 mM D-mannitol, 70 mM sucrose, 10 mM HEPES, 200 mM EGTA, 5 mM succinate, 0.15% BSA and 40 mg/ml digitonin (MSH buer). After lysis, the supernatant (cytosolic fraction) was centrifuged for 10 min at 13 000 r.p.m. The supernatant was incubated with an equal volume of 10% TCA. The samples were kept at 7208C for at least 30 min and then centrifuged for 10 min at 13 000 r.p.m. The pellets were resuspended in Laemmli buer and analysed for cytochrome c content by immunoblot analysis. The samples were also analysed for contamination due to mitochondria by immunoblot analysis for cytochrome c oxidase.
p21 Antisense studies A previously published p21 antisense phosphorothioate oligonucleotide (Poluha et al., 1996) complementary to the region around the initiation codon (5'-TCCCCAGCCGGTT-CTGACAT-3') of the p21 mRNA was purchased from Interactiva (Ulm, Germany). As a control, we used the corresponding sense oligonucleotide sequence (5'-ATGTCA-GAACCGGCTGGGGA-3'). The antisense oligonucleotide and its control contained three phosphorothioate linkages at the 3'-and 5'-ends. The 5'-ends of both oligonucleotides were conjugated to¯uorescein to monitor the transfection eciency using immuno¯uorescence microscopy. The oligonucleotides were delivered into cells using the Eectene TM transfection reagent (Quiagen, Hilden, Germany). The cells were incubated with the oligonucleotides for 6 h. Then the medium was removed, and the cells were treated with CD95L for 16 h.
